Stock listing

OTC:CSPCY CSPC Pharmaceutical Group Limited Stock

US listing (OTC) of CSPC Pharmaceutical Group Limited · home listing HKEX:1093

Follow CSPC Pharmaceutical Group Limited into a list and get an email when it puts out news.

Share price · OTC:CSPCY

$4.20 USD -0.06 (-1.4%)

Close on Oct 27, 2026

Day range
$4.20 – $4.20 USDOct 27, 2026
Market cap
$11.98B USDAt the close on Oct 27, 2026 · price × 2.85B shares outstanding
CSPC Pharmaceutical Group Limited logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
HKEX:1093 · Home$7.895 HKD+0.03 (+0.4%)82,707,972$7.865$8.025$7.60$7.865Close on Nov 2, 2026
OTC:CSPCY$4.20 USD-0.06 (-1.4%)—$4.20$4.20$4.20$4.26Close on Oct 27, 2026
OTC:CHJTF$1.11 USD0.00 (0.0%)—$1.11$1.11$1.11$1.11Close on Oct 27, 2026
Frankfurt:CVG€0.88 EUR+0.003 (+0.4%)—€0.88€0.88€0.88€0.877Close on Oct 30, 2026
Frankfurt:CVGU€3.24 EUR-0.02 (-0.6%)—€3.24€3.24€3.24€3.26Close on Oct 30, 2026
Munich:CVG€0.92 EUR-0.05 (-5.2%)—€0.92€0.92€0.92€0.97Close on Oct 27, 2026
Ticker
OTC:CSPCY
Asset type
Stock
Exchange
OTC
Currency
USD

What changed lately

Latest news

Monthly return of equity issuer on movements in securities for the month ended 31 October 2026

Nov 2, 2026

Voluntary announcement - phase iii clinical trial of prusogliptin tablets in combination with dapagliflozin tablets and metformin hydrochloride extended-release tablets for the treatment of type 2 diabetes mellitus achieves positive topline results

Nov 2, 2026

Voluntary announcement - phase i/ii clinical trial of SYS6052 (recombinant herpes zoster virus vaccine (cho cells)) officially initiated in china

Nov 2, 2026

Voluntary announcement - phase i clinical trial of SYS6057 (recombinant respiratory syncytial virus vaccine (cho cells)) officially initiated in china

Nov 2, 2026

Voluntary announcement - phase i/ii clinical trial of SYS6043 for the treatment of advanced solid tumours officially initiated at the first centre in china

Oct 30, 2026

Unaudited financial information of cspc innovation pharmaceutical co., ltd. for the nine months ended 30 September 2026

Oct 28, 2026

Voluntary announcement - phase i clinical trial of SYS6077 injection for the treatment of advanced malignant tumours officially initiated at the first centre in china

Oct 28, 2026

Voluntary announcement - results from a phase i/ii clinical study of SYS6043 (B7-H3 adc) for the treatment of advanced breast cancer presented as a rapid oral presentation at the esmo congress 2026

Oct 27, 2026

Voluntary announcement - results from a phase i/ii clinical study of anti-PD-1/IL-15 bifunctional fusion protein SYS6090 (JMT108) monotherapy in advanced solid tumours presented as a rapid oral presentation at the esmo congress 2026

Oct 27, 2026

Voluntary announcement - results from a phase iii clinical study of anbenitamab in combination with docetaxel for injection (albumin-bound) (HB1801) for the first-line treatment of HER2-positive advanced breast cancer presented as a proffered paper presentation at the esmo congress 2026 and simultaneously published in the new england journal of medicine

Oct 26, 2026

All CSPC Pharmaceutical Group Limited news

Decks

CSPC Pharmaceutical Group Limited on 6ix

News releases
35 in the last 12 months · 60 in all · newest Nov 2, 2026 · oldest 2020
Decks
17 decks · latest August 2026

Where CSPC Pharmaceutical Group Limited is listed

ListingExchangeCountryCurrency
HKEX:1093 石藥集團 · Home listingHKEXHong KongHKD
OTC:CSPCY · This pageOTCUnited StatesUSD
LS Exchange:548183LS ExchangeGermanyEUR
gettex:CVGgettexGermanyEUR
OTC:CHJTFOTCUnited StatesUSD
Lang & Schwarz:548183Lang & SchwarzGermanyEUR
Frankfurt:CVGFrankfurtGermanyEUR
Tradegate:CVGTradegateGermanyEUR
BMV:1093NBMVMexicoMXN
Dusseldorf:CVGDusseldorfGermanyEUR
Frankfurt:CVGUFrankfurtGermanyEUR
Hanover:CVGHanoverGermanyEUR
Munich:CVGMunichGermanyEUR
BIVA:1093NBIVAMexicoMXN
Stuttgart:CVGStuttgartGermanyEUR

Log in to ask 6ix AI your own questions about CSPC Pharmaceutical Group Limited.